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Abstract
Background: In the treatment of lung cancer, an accurate estimation of patient clinical outcome is essential for choosing an
appropriate course of therapy. It is important to develop a prognostic stratification model which combines clinical,
pathological and demographic factors for individualized clinical decision making.
Methodology/Principal Findings: A total of 234,412 patients diagnosed with adenocarcinomas or squamous cell
carcinomas of the lung or bronchus between 1988 and 2006 were retrieved from the SEER database to construct a
prognostic model. A model was developed by estimating a Cox proportional hazards model on 500 bootstrapped samples.
Two models, one using stage alone and another comprehensive model using additional covariates, were constructed. The
comprehensive model consistently outperformed the model using stage alone in prognostic stratification and on Harrell’s C,
Nagelkerke’s R
2, and Brier Scores in the whole patient population as well as in specific treatment modalities. Specifically, the
comprehensive model generated different prognostic groups with distinct post-operative survival (log-rank P,0.001) within
surgical stage IA and IB patients in Kaplan-Meier analyses. Two additional patient cohorts (n=1,991) were used as an
external validation, with the comprehensive model again outperforming the model using stage alone with regards to
prognostic stratification and the three evaluated metrics.
Conclusion/Significance: These results demonstrate the feasibility of constructing a precise prognostic model combining
multiple clinical, pathologic, and demographic factors. The comprehensive model significantly improves individualized
prognosis upon AJCC tumor staging and is robust across a range of treatment modalities, the spectrum of patient risk, and
in novel patient cohorts.
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Introduction
Lung cancer is one of the most aggressive cancer types and
consistently the leading cause of cancer-related death in the
United States for both men and women. There are around
215,000 new cases and 161,000 deaths annually [1]. Non-small
cell lung cancer (NSCLC) accounts for about 80% of lung cancer
cases. Although tumor stage is strongly predictive of survival in
most cases, it does not explain the distinct variability in treatment
outcome within patients of the same stage. Currently, surgery is
the major treatment option for patients with stage I NSCLC.
However, 35–50% of stage I NSCLC patients will relapse within
five years [2,3], which is the major cause of treatment failure, i.e.
death from lung cancer. It remains an unsolved challenge for
physicians to reliably identify patients at high risk for tumor
recurrence as candidates for adjuvant chemotherapy.
Recent studies have utilized a variety of information in addition
to tumor stage for prognostic stratification and prediction of
treatment outcome [4–12]. Prognostic factors such as age, gender,
and tumor grade, have been shown to be strongly associated with
survival. Age is a well established risk factor for the development of
lung cancer and can also influence the type of treatment received
either due to medical coverage or the existence of co-morbid
conditions which preclude certain therapies [13,14]. Males
diagnosed with lung cancer consistently experience poorer survival
than do females [15]. This gender difference persisted even when
controlling for other variables such as tumor stage, age at
diagnosis, and treatment.
Race has also been shown to be a significant predictor of
survival, with Asians and Pacific Islanders experiencing better
survival in both prospective [16] and population-based studies
[17]. While the disease mechanism and genetic background is not
well characterized, the consistency of this finding is useful in terms
of prognostication and treatment.
The emerging use of genetic markers may enable physicians
to make treatment decisions based on the specific characteristics
of individual patients and their tumors, instead of population
statistics [18]. This study presents an alternative avenue to
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clinical, pathological, and demographic factors in a popula-
tion-based study (n=234,412). This comprehensive model was
tested across a number of treatment modalities and blindly
validated on multiple separate patient cohorts (n=1,991). The
comprehensive model achieved a significant improvement in
prognostication when compared with AJCC tumor staging
system including cases converted to AJCC 7
th Edition [19].
This patient stratification scheme could be integrated with future
clinically-validated prognostic gene signatures for personalized
prognosis of NSCLC.
Methods
Acquisition of Patient Cohorts
A cohort of patients diagnosed with lung cancer was retrieved
from the Surveillance Epidemiology and End Results (SEER)
database [20]. The SEER database is an aggregate of registry data
from specific geographic areas covering approximately 26 percent
of the U.S. population, and contains clinical, demographic,
treatment, and follow-up information for a variety of cancers.
The requirements for inclusion in the study included a diagnosis of
primary lung adenocarcinoma (ICD-O-3 8140 to 8380) or
squamous cell carcinoma (ICD-O-3 8050 to 8080) between the
years 1988 and 2006, as well as available data on tumor stage,
tumor grade, race, age, gender, disease-specific survival, and
treatment. Patients who were diagnosed via autopsy or death
certificate, or had no valid survival data were excluded from the
analysis. A total of 234,412 patients met the inclusion criteria.
Patients staged using the 6
th edition of AJCC staging, in general
2004 and newer diagnoses, were recoded to the 7
th edition based
on the proposed staging changes in the AJCC Staging Manual
[19] and information about tumor size, extension, metastasis, and
lymph node involvement found in the SEER database where
possible. A total of 58,634 cases were able to be converted from
the 6
th to the 7
th edition.
Two additional patient cohorts were also used as validation
sets. De-identified data for a total of 1,552 patients treated at the
Mary Babb Randolph Cancer Center at West Virginia University
from 1990 to 2009 with squamous cell carcinoma (n=758) or
adenocarcinoma (n=794) were obtained. The study was
approved with an IRB exemption from West Virginia University.
According to HIPAA regulation, de-identified clinical informa-
tion can be used in research without prior consent from the
patients. A total of 439 lung adenocarcinoma cases were also
obtained from Shedden et al [21] for patients with Stage I-IIIB
cancers. These patients were treated in H. Lee Moffitt Cancer
Center, University of Michigan Comprehensive Cancer Center,
Dana-Farber Cancer Institute, and Memorial Sloan-Kettering
Cancer Center. Patients have provided consent. These data have
been published in Shedden et al [21] before. It is not clear if
patients have provided written or verbal consent. The protocols
were approved with Institutional Review Boards (IRB-Med) of
the respective institutes.
Conversion of Cases to AJCC 7
th Edition
Cases diagnosed from 2004 onward were able to be converted
into the AJCC 7
th Edition. The original TNM staging information
regarding tumor size and extension (T), lymph node status (N), and
distant metastasis (M) was retrieved from the SEER data. Using
this information, the T, N, and M classifiers were recoded
according to the new guidelines [19] and then used to determine
the AJCC 7
th Edition stage.
Model Construction and Statistical Analyses
Disease-specific survival was analyzed primarily using a Cox
proportional hazards model. This model estimates the effect of
covariates on the time until an event, in this case death, following a
diagnosis. Four models, one for each of the histology and AJCC
staging combinations, were estimated. A total of 500 bootstrapped
samples equal in size to the original adenocarcinoma and
squamous cell carcinoma patient cohorts were constructed. This
method has been seen to be superior to split-sample techniques
[22], and in general produces less biased estimates with a smaller
variance. A Cox model was then fit on each bootstrapped sample.
In order to determine the advantage of using other covariates in
addition to AJCC stage, two sets of covariates were used in the
model evaluation. The first contained information on tumor stage
and grade, patient age, race, and gender. The second contained
only information on tumor stage and was used as a model of
current clinical practice. The final training model used the mean
value of all coefficients generated from the bootstrapped samples,
as the distribution of hazard scores was normal. Hazard scores
were calculated for each patient in the original samples based on
the final model constructed from the means. The formula used to
specify the model is shown below, demonstrating the relationship
between hazard h for patient i at time t and the coefficients, b, for
covariates 1 through k with values of x.
loghi(t)~a(t)zb1xi1zb2xi2zzbkxik
In the prognostic categorization, cutoff values were defined
from the bootstrapped samples to stratify patients into a high-,
low-, or intermediate-risk group based on their individual hazard
scores. The Cox-model and cutoff values were applied to the
original cohort for validation. The prognostic categorization was
evaluated with the Kaplan-Meier survival function, where the
estimated proportion surviving S at any time t is equal to the
proportion of non-censored cases n surviving interval i less the
number of deaths d in that interval, as in the following formula:
S(t)~ P
tivt
ni{d
ni
Patients still alive or dead due to unrelated causes were censored
at the time of last follow-up or death, respectively. Internal
performance was measured using Harrell’s C, Nagelkerke’s R
2,
and Brier Scores. Harrell’s C is a measure of concordance which is
representative of the area under an ROC curve ranging between 0
and 1, with higher scores indicating greater concordance [23]. The
ROC curves were used in model evaluation with the pROC
package in R. The statistical significance (P-value) of the difference
between the areas under the curves was calculated using the
Delong method in the same package. A larger area in this case
demonstrates an improved predictive ability. Nagelkerke’s R
2 is
functionally similar to the R
2 value in linear models, ranging
between 0 and 1 with higher values explaining more variance, with
this variant being calculated on the log-likelihood scale. The Brier
score represents the average prediction error, ranging from 1 to 0,
with lower values indicating a lower average error. Significance of
risk-group stratification was determined using a log-rank test of the
Kaplan-Meier function. The log-rank test uses contingency tables
at each observation period to determine if a significant difference
exists between two survival functions. The model constructed
using the training set was then further validated on SEER sub-
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Challenge cohorts [21], without re-estimating parameters of the
model or cutoffs. Statistical analyses were conducted with the pamr,
pec, Design, and survival packages in R v2.11.0.
Results
This study focused on two major cell types of NSCLC, lung
adenocarcinoma and squamous cell carcinoma. For each cell
type, a comprehensive model was constructed to include the
previous AJCC staging system (the 3
rd and 6
th editions) and the
current AJCC 7
th edition. The clinical characteristics of the
SEER patient population are listed in Table 1, and two external
validation cohorts are summarized in Table 2. The bootstrapped
model was used to generate a hazard score of each patient in the
test data as a blinded validation. The previously determined
parameters and cutoffs were used to stratify patients in the
original cohort into the three risk groups based on the hazard
score of each patient. The prognostic categorization of the
comprehensive model was compared with multiple editions of
the AJCC staging system. Specifically, the low-risk group defined
by the comprehensive model was compared with AJCC stage I;
the intermediate-risk group was compared with AJCC stage II
and IIIA; whereas the high-risk group was compared with AJCC
stage IIIB/IV. Significantly longer survival in the low-risk group
or significantly poorer survival in the high-risk group was
considered to be an improvement in prognostication using the
comprehensive model. The models were constructed by taking
the mean of each coefficient from a Cox model fit on 500
bootstrapped samples of each original cohort. This resulted in a
total of four models, one for each of the two AJCC staging
systems combined with two major NSCLC cell types. These
models were tested on the original samples in their entirety, sub-
cohorts representative of four major treatment modalities, and
two external cohorts.
In the overall studied patient population, earlier stage at
diagnosis was significantly related to disease-specific survival in a
univariate Cox Proportional Hazards model in both adenocarci-
noma and squamous cell carcinoma for each AJCC Staging system
(P,0.05). In the multivariate analyses AJCC stage, tumor grade,
patient age, race, and gender were all significant. Specifically,
lower tumor grade, younger age at diagnosis, and being of Asian/
Pacific Islander descent were all significantly associated with
improved survival (P,0.05). Being male or having a later stage at
diagnosis was associated with a poorer outcome across all groups.
The comprehensive model incorporating all these factors showed
significantly improved prognostic categorization when compared
with the AJCC staging system, including the latest edition which is
detailed below.
The patients were then assigned into one of four treatment
categories based on the treatment record in the SEER database.
These categories were surgery, radiation, surgery with radiation,
and no treatment listed. For simplicity, this determination was
based on the presence or absence of any surgical or radiation
procedure, regardless of the specific procedure.
Table 1. Outline of patient clinical characteristics for major
histology of non-small cell lung cancer and AJCC staging
editions retrieved from SEER database.
Adenocarcinoma Squamous
Variable* AJCC 3
rd&6
th AJCC 7
th AJCC 3
rd&6
th AJCC 7
th
Age
Mean Age
(s)
66.9 (11.4) 67.0 (11.3) 69.0 (9.9) 69.8 (10.2)
Sex
Male 75,753 (50.4%) 18,550 (48.3%) 55,794 (66.2%) 12,678 (62.7%)
Race
API 10,377 (6.9%) 2,853 (7.4%) 3,877 (4.6%) 885 (4.4%)
Black 14,432 (9.6%) 3,620 (9.4%) 10,373 (12.3%) 2,317 (11.5%)
White 125,349 (83.5%) 31,953 (83.2%) 70,004 (83.1%) 17,006 (84.2%)
Tumor Stage
I 36,052 (24%) 8,295 (21.6%) 21,495 (25.5%) 4,090 (20.2%)
II 6,118 (4.1%) 4,661 (12.1%) 4,899 (5.8%) 3,026 (15%)
IIIA 11,447 (7.6%) 5,773 (15%) 11,284 (13.4%) 4,497 (22.2%)
IIIB 26,905 (17.9%) 3,008 (7.8%) 19,933 (23.7%) 2,435 (12%)
IV 69,636 (46.4%) 16,690 (43.4%) 26,643 (31.6%) 6,160 (30.5%)
Tumor Grade
Grade 1 11,415 (7.6%) 3,602 (9.4%) 2,559 (3.0%) 464 (2.3%)
Grade 2 28,999 (19.3%) 8,637 (22.4%) 22,877 (27.2%) 5,700 (28.2%)
Grade 3 45,424 (30.3%) 9,796 (25.5%) 32,380 (38.4%) 7,266 (36%)
Grade 4 64,320 (42.8%) 16,391 (42.7%) 26,438 (31.4%) 6,779 (33.5%)
*Sub-stages for stage I and II patients are combined as it was not possible to
differentiate between sub-stages for all patients staged with the AJCC 3
rd and
6
th staging systems. Age is represented as the mean age with the standard
deviation in parentheses.
doi:10.1371/journal.pone.0017493.t001
Table 2. Outline of patient clinical characteristics for external
non-small cell lung cancer validation sets.
Adenocarcinoma Squamous
Variable
Director’s Challenge
Study [21] MBRCC MBRCC
Age*
Mean Age (s) 64.4 (10.1) 64.3 (11.3) 67.1 (10.1)
Sex
Male 218 (50.3%) 419 (52.8%) 479 (63.2%)
Race
API 7 (1.6%) 2 (0.3%) 1 (0.1%)
Black 12 (2.7%) 9 (1.1%) 15 (2.0%)
White 420 (95.7%) 783 (98.6%) 742 (97.9%)
Tumor Stage
I 276 (62.9%) 181 (22.8%) 176 (23.2%)
II 95 (21.6%) 48 (6%) 57 (7.5%)
IIIA 57 (13%) 74 (9.3%) 111 (14.6%)
IIIB 11 (2.5%) 95 (12%) 115 (15.2%)
IV 0 (0%) 396 (49.9%) 299 (39.4%)
Tumor Grade
Grade 1 60 (13.7%) 62 (7.8%) 22 (2.9%)
Grade 2 208 (47.4%) 137 (17.2%) 172 (22.6%)
Grade 3 166 (37.8%) 231 (29%) 267 (35.2%)
Grade 4 5 (1.1%) 364 (45.8%) 297 (39.2%)
*Age is represented as the mean age with the standard deviation in
parentheses.
doi:10.1371/journal.pone.0017493.t002
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3
rd and 6
th edition)
A total of 150,158 lung adenocarcinoma patients staged with the
3
rd and 6
th AJCC Editions met the criteria for inclusion. Harrell’s c
statistic was calculated for both the model using stage alone and the
comprehensive model using additional covariates. The compre-
hensive model had a higher C statistic (0.732) compared to the stage
only model (0.694), as well as showing better prediction of 5-year
survival after the initial treatment in ROC curves (P,0.0001,
Fig. 1A). A similar improvement was seen for Nagelkerke’s R
2
(0.294 vs. 0.253) and Brier score (0.134 vs. 0.143).
The analysis comparing the performance of each model on
treatment subgroups also showed a similar improvement in
predictive ability with the comprehensive model. In patients that
received surgery without radiation, the comprehensive model had
consistently better estimates for Harrell’s C (0.768 vs. 0.723),
Nagelkerke’s R
2 (0.225 vs. 0.173) and Brier Score (0.206 vs. 0.210).
A similar improvement, summarized in Tables 3, 4 and 5, was
observed in patients receiving radiation without surgery, surgery
with radiation, and those with no treatment listed.
The low-risk group predicted by the comprehensive model
survived significantly longer than stage I patients, with an average
survival of 69.6 versus 57.2 months (log-rank P,0.0001). In
addition, the high-risk group predicted by the comprehensive
model had a significantly poorer survival than the stage IIIB/IV
patient group, with an average survival of 5.6 months compared to
11.9 months (log-rank P,0.0001) as shown in Fig. 2C and 2D.
For lung adenocarcinoma patients who received surgery
without radiation, the comprehensive model was able to improve
upon the prognostic ability of AJCC staging for low-risk patients
with an average survival of 72.4 versus 62.3 months (log-rank
P,0.0001). Patients in the high-risk group had an average survival
of 13.3 versus 30.6 months for the comprehensive and stage alone
models, respectively (log-rank P,0.0001). The intermediate-risk
group defined by the comprehensive model showed significantly
better prognosis than stage II and III patients (log-rank P,0.0001;
Fig. 2E and 2F). Similar results were observed for patients
receiving other treatment options (results not shown). Specifically,
for patients who received both surgery and radiation, radiation
without surgery, or no treatment, the comprehensive model could
identify patients at higher risk as candidates for adjuvant
chemotherapy, whereas it might spare low-risk patients from
unnecessarily aggressive treatment.
Lung adenocarcinoma cases converted to the AJCC 7
th
edition
A total of 38,426 lung adenocarcinoma cases were converted
into the AJCC 7
th edition. It is important to note that the
Figure 1. Prediction of survival at 60 months for the AJCC 3
rd and 6
th Editions (top) and 30 months for the cases converted to the
AJCC 7
th Edition (bottom) for both lung adenocarcinoma (left) and squamous cell lung cancer (right) using ROC curves. P,0.05
indicates that the full model is significantly more accurate in predicting disease-specific survival than tumor stage.
doi:10.1371/journal.pone.0017493.g001
Lung Cancer Prognosis
PLoS ONE | www.plosone.org 4 February 2011 | Volume 6 | Issue 2 | e17493Table 4. Nagelkerke’s R
2 values from each model for each of the patient cohorts, separated into AJCC coding system, treatment
modality, and histology where possible.
Lung Adenocarcinoma Squamous Cell Lung Carcinoma
AJCC 3
rd &6
th AJCC 7
th AJCC 3
rd &6
th AJCC 7
th
FM SO FM SO FM SO FM SO
All SEER Patients 0.294 0.253 0.305 0.274 0.289 0.274 0.246 0.230
Surgery 0.225 0.173 0.094 0.073 0.283 0.268 0.064 0.055
Radiation 0.107 0.084 0.140 0.115 0.109 0.103 0.120 0.118
Surgery + Radiation 0.204 0.178 0.084 0.072 0.201 0.184 0.095 0.089
No Treatment 0.066 0.034 0.075 0.044 0.051 0.042 0.065 0.054
MBRCC Cohort 0.343 0.311 N/A N/A 0.244 0.233 N/A N/A
Director’s Challenge Study 0.189 0.162 N/A N/A N/A N/A N/A N/A
FM: full model; SO: AJCC stage only.
doi:10.1371/journal.pone.0017493.t004
Table 5. Brier Scores from each model for each of the patient cohorts, separated into AJCC coding system, treatment modality,
and histology where possible.
Lung Adenocarcinoma Squamous Cell Lung Carcinoma
AJCC 3
rd &6
th AJCC 7
th AJCC 3
rd &6
th AJCC 7
th
FM SO FM SO FM SO FM SO
All SEER Patients 0.134 0.143 0.144 0.150 0.119 0.119 0.162 0.161
Surgery 0.206 0.210 0.089 0.092 0.186 0.188 0.113 0.114
Radiation 0.097 0.099 0.163 0.168 0.102 0.102 0.170 0.172
Surgery + Radiation 0.096 0.097 0.153 0.154 0.098 0.099 0.160 0.163
No Treatment 0.098 0.101 0.167 0.178 0.078 0.081 0.151 0.152
MBRCC Cohort 0.071 0.074 N/A N/A 0.079 0.081 N/A N/A
Director’s Challenge Study 0.163 0.170 N/A N/A N/A N/A N/A N/A
FM: full model; SO: AJCC stage only.
doi:10.1371/journal.pone.0017493.t005
Table 3. Harrell’s C-statistics from each model for each of the patient cohorts, separated into AJCC coding system, treatment
modality, and histology where possible.
Lung Adenocarcinoma Squamous Cell Lung Carcinoma
AJCC 3
rd &6
th AJCC 7
th AJCC 3
rd &6
th AJCC 7
th
FM SO FM SO FM SO FM SO
All SEER Patients 0.732 0.694 0.763 0.731 0.722 0.706 0.733 0.717
Surgery 0.768 0.723 0.742 0.707 0.762 0.742 0.689 0.670
Radiation 0.631 0.608 0.665 0.632 0.647 0.636 0.666 0.658
Surgery + Radiation 0.688 0.677 0.696 0.678 0.688 0.674 0.682 0.663
No Treatment 0.601 0.542 0.607 0.558 0.582 0.567 0.598 0.580
MBRCC Cohort 0.721 0.708 N/A N/A 0.695 0.681 N/A N/A
Director’s Challenge Study 0.687 0.660 N/A N/A N/A N/A N/A N/A
FM: full model; SO: AJCC stage only.
doi:10.1371/journal.pone.0017493.t003
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shorter follow-up time compared to the AJCC 3
rd and 6
th Edition
cohorts. When considering the entire patient sample, Harrell’s C
for the comprehensive model versus the stage only model (0.763
vs. 0.731), prediction of survival at 30 months (P,0.0001,
Fig. 1C), Nagelkerke’s R
2 (0.305 vs. 0.274) and Brier score (0.144
vs. 0.150) were all improved. These effects persisted when
considering the four patient sub-cohorts defined by treatment
modality, although the performance of both models was similarly
decreased when compared to the original staging system. The
patient sub-cohort with no treatment listed performed the worst
on all three metrics. An improvement in the prognostic
categorization similar to that observed in the unconverted cases
(the AJCC 3
rd and 6
th staging) was found for the overall
population and specific treatment modalities (Fig. 3). When
considering all treatments the low-risk group predicted by the
comprehensive model had an average survival of 16.4 months
compared to 15.3 months for stage I of the AJCC 7
th edition (log-
rank P,0.0001). Prediction of the high-risk group was also
significantly improved with an average survival of 2.0 months for
Figure 2. Results of survival analysis on lung adenocarcinoma patients staged using AJCC 3
rd or 6
th Edition. a) Histogram of Hazard
Scores obtained from the comprehensive model. b) Probability of death from lung cancer prior to 24 months based on Hazard Scores calculated
using the comprehensive model. c) Kaplan-Meier survival plots for low-, intermediate-, and high-risk groups determined by the comprehensive model
(blue) and AJCC staging alone (orange). d) Average survival of each group in months, with log-rank P-values shown. L: low-risk; Int: intermediate-risk;
H: high-risk defined by the full model. Stage only model contains patient with stage 1, 2, 3a, 3b and 4. e) Kaplan-Meier survival plots for each risk
group in patients who received surgery without radiation. f) Average survival for risk groups in patients who received surgery without radiation. L:
low-risk; Int: intermediate-risk; H: high-risk. Stage only model contains patient with stage 1, 2, 3a, 3b and 4.
doi:10.1371/journal.pone.0017493.g002
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rank P,0.0001).
For lung adenocarcinoma patients who received surgery
without radiation, the comprehensive model significantly im-
proved prognostication in the low-risk group (16.5 versus 16.0
months, log-rank P,0.0001). The high-risk group had an average
survival of 4.3 months for the comprehensive model and 8.9
months for stage IIIB/IV (log-rank P,0.0001)). The comprehen-
sive model was also able to improve prognostication for both the
high and low-risk groups in patients that received both surgery and
radiation or no treatment (P,0.05), and in the high-risk group for
patients receiving radiation without surgery (P,0.0001). Prognos-
tication using the comprehensive model matched or improved
non-significantly upon the stage only model in the patient samples
which did not achieve significance (results not shown).
Prognostication of squamous cell lung cancer (the AJCC
3
rd and 6
th edition)
A total of 84,254 squamous cell lung cancer patients diagnosed
with the ACC 3
rd and 6
th staging system met the inclusion
Figure 3. Results of survival analysis on lung adenocarcinoma patients converted to AJCC 7
th Edition. a) Histogram of Hazard Scores
obtained from the comprehensive model. b) Probability of death from lung cancer prior to 24 months based on Hazard Scores calculated using the
comprehensive model. c) Kaplan-Meier survival plots for low-, intermediate-, and high-risk groups determined by the comprehensive model (blue)
and AJCC staging alone (orange). d) Average survival of each group in months, with log-rank P-values shown. e) Kaplan-Meier survival plots for each
risk group in patients who received surgery without radiation. f) Average survival for risk groups in patients who received surgery without radiation. L:
low-risk; Int: intermediate-risk; H: high-risk defined by the full model. Stage only model contains patient with stage 1, 2, 3a, 3b and 4.
doi:10.1371/journal.pone.0017493.g003
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models were slightly decreased when compared to the adenocar-
cinoma patients in the overall patient sample. However, there
was still an improvement in the overall treatment cohort when
using the comprehensive model on Harrell’s C (0.722 vs. 0.706),
prediction of 5-year survival in ROC curves (P,0.0001Fig. 1B),
Nagelkerke’s R
2 (0.289 vs. 0.274), but not on Brier score (0.119
vs. 0.119). There was a similar improvement in the sub-cohorts
defined by treatment modality, with the comprehensive model
performing as well or better than the stage only model in all sub-
cohorts. In the overall cohort, the low-risk group defined by the
comprehensive model had an average survival of 51.3 months
versus 45.7 months in stage I squamous cell lung cancer (log-rank
P,0.0001). The high-risk group had an average survival of 1.7
months versus 4.7 months in stage IIIB/IV patients (log-rank
P,0.0001).
Similar results were found when comparing only those who
received surgical treatment, with the low-risk group predicted by
Figure 4. Results of survival analysis on squamous cell lung cancer patients staged using AJCC 3
rd or 6
th Edition. a) Histogram of
Hazard Scores obtained from the comprehensive model. b) Probability of death from lung cancer prior to 24 months based on Hazard Scores
calculated using the comprehensive model. c) Kaplan-Meier survival plots for low-, intermediate-, and high-risk groups determined by the
comprehensive model (blue) and AJCC staging alone (orange). d) Average survival of each group in months, with log-rank P-values shown. e) Kaplan-
Meier survival plots for each risk group in patients having received surgery without radiation. f.) Average survival for risk groups in patients who
received surgery without radiation. L: low-risk; Int: intermediate-risk; H: high-risk defined by the full model. Stage only model contains patient with
stage 1, 2, 3a, 3b and 4.
doi:10.1371/journal.pone.0017493.g004
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compared to 55.3 months for stage I patients (log-rank P,0.0001),
and the high-risk group surviving an average of 1.2 versus 9.3
months in stage IIIB/IV patients (log-rank P,0.0001; Fig. 4E and
4F). Similar results were also observed for squamous cell lung
cancer patients who received surgery and radiation, radiation
without surgery, and no treatment (results not shown) with the
comprehensive model improving prognostication among high-risk
patients in all three samples (log-rank P,0.05), and in low-risk
patients for those receiving surgery with radiation or no treatment
(log-rank P,0.05).
Squamous cell lung cancer cases converted to the AJCC
7
th edition
A total of 20,208 squamous cell lung cancer cases could be
converted to the AJCC 7
th edition. Prediction was similar or
improved when using the comprehensive model on all three
metrics and in all treatment cohorts considered, however the
difference between the two models was marginal in some cases.
The most marked improvement in prediction was in the sub-
cohort of patients receiving surgery without radiation. For that
group, the comprehensive model outperformed the stage only
model on Harrell’s C (0.689 vs. 0.670), prediction of survival at 30
Figure 5. Results of survival analysis on squamous cell lung cancer patients converted to AJCC 7
th Edition. a) Histogram of Hazard
Scores obtained from the comprehensive model. b) Probability of death from lung cancer prior to 24 months based on Hazard Scores calculated
using the comprehensive model. c) Kaplan-Meier survival plots for low-, intermediate-, and high-risk groups determined by the comprehensive model
(blue) and AJCC staging alone (orange). d.) Average survival of each group in months, with log-rank P-values shown. e) Kaplan-Meier survival plots for
each risk group in patients who received surgery without radiation. f.) Average survival for risk groups in patients who received surgery without
radiation. L: low-risk; Int: intermediate-risk; H: high-risk defined by the full model. Stage only model contains patient with stage 1, 2, 3a, 3b and 4.
doi:10.1371/journal.pone.0017493.g005
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2 (0.064 vs. 0.055),
and marginally on Brier score (0.113 vs. 0.114).
The low-risk group predicted by the comprehensive model
survived an average of 14.7 months, representing a significantly
better prognosis than average survival of 13.7 months in stage I
patients (log-rank P,0.0001). The high-risk group had an average
of 1.8 versus 3.0 months when compared to stage IIIB/IV patients
(log-rank P,0.0001).
In patients receiving surgery without radiation, the comprehen-
sive model predicted an average survival of 15.7 months for the
low-risk group versus 15.2 months for stage I (log-rank P=0.0114).
The average survival of the high-risk group did not differ
significantly from that of stage IIIB/IV (P=0.8764), due in part
to the small sample size and short follow-up, although the
comprehensive model showed a non-significant improvement of
5.0 versus 7.8 months. These results are summarized in Fig. 5. In
patients treated with radiation without surgery or radiation with
surgery, prognostic categorization was improved only in the high-
risk group, with an average survival of 2.1 versus 3.2 months and
2.4 versus 6.1 months, respectively, compared to stage alone (log-
rank P=0.0136; results not shown).
Treatment selection for stage I patients
Patients with stage I cancers who were treated with surgery
without radiation were extracted for a further analysis to
determine whether the comprehensive model could identify
early-stage patients who may benefit from a more aggressive
therapy. The stage I cohort was then further separated into stage
IA and IB patients, with the coefficients from the comprehensive
model being applied in order to test the ability of the additional
factors to stratify a relatively homogenous set of patients. High and
low-risk group membership was defined relative to the median
hazard score for each cohort. For adenocarcinoma the compre-
hensive model was able to stratify stage IA and IB using both the
3
rd and 6
th Editions as well as the 7
th Edition (log-rank P,0.0001)
in Kaplan-Meier analyses (Fig. 6). In squamous cell carcinomas
the comprehensive model was again able to significantly stratify
stage IA and IB patients into high and low-risk groups with both
AJCC staging schemes using the model developed on the entire
SEER cohort without re-estimation of the parameters (log-rank
P,0.0001; Kaplan-Meier analyses; Fig. 7). These results demon-
strate that the comprehensive prognostic model was able to
reliably identify stage I NSCLC patients at higher risk for tumor
recurrence. These high risk patients should be considered for
adjuvant chemotherapy.
External Validation
The comprehensive model was also able to improve prognos-
tication in the external validation sets from MBRCC and the
Director’s Challenge cohort [21]. Patients with both adenocarci-
nomas (n=794) and squamous cell carcinomas (n=758) with all
tumor stages were available from the MBRCC cohort. The
Director’s Challenge cohort contained only lung adenocarcinoma
patients with stage I, II, and III (n=439). The comprehensive
Figure 6. Results of survival analysis on lung adenocarcinoma patients diagnosed with stage IA or IB disease. The Kaplan-Meier plots
show the difference between low- and high-risk groups as determined by the comprehensive model. Data on sub-stage was only available for
patients staged using the AJCC 6
th Edition staging system (2004 and later) and for those patients converted into the 7
th Edition.
doi:10.1371/journal.pone.0017493.g006
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considered when the training models estimated using the SEER
cohort was applied to the cohorts from MBRCC and the
Director’s Challenge study, with the results being consistent across
histology in the MBRCC cohort. The comprehensive model
appeared to perform much better in the MBRCC cohort. These
results are summarized in Tables 3, 4, and 5.
In the adenocarcinoma cohort from MBRCC, the comprehen-
sive model was able to improve prognostication for the low-risk
group (33 versus 24 months, P=0.0170) and borderline significant
for the high-risk groups (2.2 versus 2.8 months, P=0.058). The
addition of pathological and demographic factors could not
significantly improve prognostication in the squamous cell
carcinoma patients from the same set (P.0.05). In the Director’s
Challenge cohort which contained only adenocarcinomas, the
comprehensive model was able to improve prognostication for the
low-risk (42.6 versus 36.2 months) and the high-risk group (2.2
versus 9.2 months), although the results were not significant
(P.0.05). These results are illustrated in Fig. 8.
Discussion
Substantial efforts have been made to establish prognostic
factors for patients with lung cancer during the last two decades.
The traditional prognostic factors are tumor size, vascular
invasion, poor differentiation, high tumor-proliferative index,
and genetic alterations, including K-ras [24,25] and p53 [26].
With the development of molecular biotechnology, especially
high-throughput microarrays, there have been a number of
promising studies on lung cancer prognosis by transcriptional
profiling [21,27–35]. Although the traditional prognostic factors
lack the information about the biological diversity of lung cancer
and have not reflected the complexity of molecular mechanisms of
these diseases, they are still the most valuable criteria for clinicians
to decide the relevant therapies [36]. For instance, Adjuvant!
(www.adjuvantonline.com) is a prognostic system for lung cancer,
breast cancer, and colon cancer based on traditional pathological
features, including age, tumor stage, and grade. It has been
independently validated as a reliable aid to clinical decision-
making on average breast cancer patients [37]. A study by Birim
and others [38] also demonstrated that clinical factors such as
respiratory function, comorbidity, and smoking behaviors in
addition to tumor stage could be used to refine prognosis in a
cohort of NSCLC patients (n=766).
In this study, we sought to investigate the impact of clinical,
pathological, and demographic factors on lung cancer survival
using a population-based approach. It was found that the addition
of pathological and demographic covariates to AJCC staging was
able to significantly improve predictive ability in both lung
adenocarcinomas and squamous cell carcinomas. These additional
variables accounted for previously unexplained variation within
and independent of tumor stage, and resulted in a more accurate
assessment of the risk for treatment failure when evaluated as
integrated prognostic indicators. This effect persisted within
multiple treatment modalities.
The comprehensive model was able to improve prediction in
stage I surgical adenocarcinoma patients, and was able to produce
Figure 7. Results of survival analysis on squamous cell lung carcinoma patients diagnosed with Stage IA or IB disease. The Kaplan-
Meier plots show the difference between low- and high-risk groups as determined by the comprehensive model. Data on sub-stage was only
available for patients staged using the AJCC 6
th Edition staging system (2004 and later) and for those patients converted into the 7
th Edition.
doi:10.1371/journal.pone.0017493.g007
Lung Cancer Prognosis
PLoS ONE | www.plosone.org 11 February 2011 | Volume 6 | Issue 2 | e17493a significant stratification even within sub-stage IA and IB. Low-
risk patients defined by the comprehensive model may not benefit
from additional therapies while, conversely, those who are
predicted as high-risk may benefit from adjuvant chemotherapy.
The comprehensive model demonstrated significant improve-
ment in clinical prediction over the AJCC 7
th staging edition
despite smaller sample sizes and shorter follow-up. Furthermore,
the external validation results indicate that the comprehensive
prognostic model constructed from SEER population data could
improve prognosis in multiple local hospitals. These findings show
promise for a clinical model for more refined prognosis of
NSCLC.
It is important to note that the analysis does not account for the
varying quality of treatments between institutions. Median county
income was used as a rough surrogate measure for this factor in an
unpublished analysis. It was found that higher median county
income was significantly associated with improved disease-specific
survival, but was omitted from the prognostic model as it is not a
prudent metric to guide personalized treatment. Removal of
median income as a covariate did not have a significant impact on
the overall results or the predictive ability of the model as a whole.
An additional limitation of the study was the lack of information
on the use of chemotherapy and co-morbidities present at the time
of diagnosis [39]. It is expected that inclusion of data found in the
linked SEER-Medicare database will more appropriately address
these issues and allow for further refinement of the model. In
future research, we plan to construct a comprehensive model to
estimate treatment benefits of commonly used chemotherapies
Figure 8. Results of survival analyses performed on patient cohorts from the Director’s Challenge Study and the Mary Babb
Randolph Cancer Center at West Virginia University.
doi:10.1371/journal.pone.0017493.g008
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according to a specific treatment approach. A web-based
implementation of this model is currently under development,
offering nomograms representing benefits for multiple treatment
modalities. We envision that this model could be combined with
future clinically validated gene signatures for a more refined
assessment of patient risk of treatment failures for a variety of
modalities.
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